Brokerages Set Shire PLC (SHP) Target Price at $5,323.33
Shire PLC (LON:SHP) has received a consensus rating of “Buy” from the twenty analysts that are presently covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is GBX 5,323.33 ($73.55).
Several brokerages have recently issued reports on SHP. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a GBX 5,300 ($73.22) target price on shares of Shire in a research report on Monday, October 30th. Shore Capital reiterated a “buy” rating on shares of Shire in a research report on Monday, January 15th. Liberum Capital dropped their target price on shares of Shire from GBX 4,400 ($60.79) to GBX 4,200 ($58.03) and set a “hold” rating on the stock in a research report on Tuesday, October 24th. Barclays reiterated an “equal weight” rating and issued a GBX 4,000 ($55.26) target price on shares of Shire in a research report on Monday, October 30th. Finally, Deutsche Bank reiterated a “buy” rating on shares of Shire in a research report on Monday, December 11th.
In other news, insider Dominic Blakemore bought 165 shares of Shire stock in a transaction on Tuesday, December 19th. The shares were bought at an average cost of GBX 3,790 ($52.36) per share, with a total value of £6,253.50 ($8,639.82).
TRADEMARK VIOLATION NOTICE: This news story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://theolympiareport.com/2018/02/13/brokerages-set-shire-plc-shp-target-price-at-5323-33.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.